---
schema_version: "secwatch.filing_event.v1"
accession: "0001601485-24-000032"
form_type: "8-K"
ticker: "ELTX"
cik: "0001601485"
company_name: "Elicio Therapeutics, Inc."
filed_at: "2024-05-15T23:59:59+00:00"
generated_at: "2026-06-01T23:06:45.304726+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Elicio Therapeutics reports Q1 2024 net loss of $11.8M; provides clinical updates for ELI-002

## Summary
- Net loss $11.8M ($1.15 per share) vs $8.0M in Q1 2023; R&D expense increased to $7.6M from $5.5M.
- Cash and equivalents $11.9M as of March 31, 2024, down from $12.9M at December 31, 2023.
- ELI-002 2P Phase 1 data published in Nature Medicine; ELI-002 7P Phase 1 preliminary data at ASCO in June 2024.
- Randomized Phase 2 trial of ELI-002 7P enrollment expected to complete in Q4 2024; interim analysis in Q1 2025.

## SEC filing metadata
- accession: 0001601485-24-000032
- form_type: 8-K
- ticker: ELTX
- cik: 0001601485
- company_name: Elicio Therapeutics, Inc.
- filed_at: 2024-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601485/000160148524000032/0001601485-24-000032-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601485/000160148524000032/angn-20240515.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001601485-24-000032
- JSON: https://secwatch.observer/filing/0001601485-24-000032.json
- Plain text: https://secwatch.observer/filing/0001601485-24-000032.txt

## Key facts
- Earnings Releases
  Elicio Therapeutics, Inc. reported the first quarter ended March 31, 2024 results: net income $11.8 million, EPS $1.15.
  - Period: the first quarter ended March 31, 2024
  - Net income: $11.8 million
  - EPS: $1.15
  - Result: reported results
  source text: Net loss for the first quarter of 2024 was $11.8 million, compared to $8.0 million for the first quarter of 2023. Net loss per share for the first quarter of 2024 was $1.15 compared to $24.77 for the first quarter of 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1601485/000160148524000032/0001601485-24-000032-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.